Evidence map›Paper›PMID 34899322›Full record

ReviewFrontiers in pharmacology2021

A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.

Abisola Abisoye-Ogunniyan, Isabella M Carrano, Dina R Weilhammer, Sean F Gilmore, Nicholas O Fischer, Sukumar Pal, Luis M de la Maza, Matthew A Coleman, Amy Rasley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abisola Abisoye-OgunniyanBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Isabella M CarranoDepartment of Plant and Microbial Biology, Rausser College of Natural Resources, University of California, Berkeley, Berkeley, CA, United States.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Sean F GilmoreBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Nicholas O FischerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Sukumar PalDepartment of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States.
Luis M de la MazaDepartment of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States.
Matthew A ColemanBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Amy RasleyBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Funding

Project 1. Nanolipoprotein-supported multi-subunit vaccine for Chlamydia trachomatisU19AI144184 · NIAID · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI D'HAESELEER, PATRIK · 2019 to 2023
$10.0M
NIAID NIH HHS U19 AI144184
6 · The paper itself

Abstract

A worldwide estimate of over one million STIs are acquired daily and there is a desperate need for effective preventive as well as therapeutic measures to curtail this global health burden. Vaccines have been the most effective means for the control and potential eradication of infectious diseases; however, the development of vaccines against STIs has been a daunting task requiring extensive research for the development of safe and efficacious formulations. Nanoparticle-based vaccines represent a promising platform as they offer benefits such as targeted antigen presentation and delivery, co-localized antigen-adjuvant combinations for enhanced immunogenicity, and can be designed to be biologically inert. Here we discuss promising types of nanoparticles along with outcomes from nanoparticle-based vaccine preclinical studies against non-viral STIs including chlamydia, syphilis, gonorrhea, and recommendations for future nanoparticle-based vaccines against STIs.

Indexed as

chlamydiadelivery platformsgonorrheaimmunogenicitynanoparticlesSTIssyphilisvaccines

Identifiers

PMID34899322
PMCPMC8662999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.